Skip to main navigation Skip to search Skip to main content

Ataluren treatment of patients with nonsense mutation dystrophinopathy

Research output: Contribution to journal › Article

Abstract

Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders.
Original languageEnglish
Pages (from-to)477-487
Number of pages11
JournalMUSCLE & NERVE
Volume50
Issue number4
DOIs
Publication statusPublished - 2014

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Keywords

  • Adolescent
  • Child
  • Codon
  • Dose-Response Relationship
  • Double-Blind Method
  • Drug
  • Duchenne
  • Duchenne muscular dystrophy
  • Dystrophin
  • Humans
  • International Cooperation
  • Male
  • Muscular Dystrophy
  • Nonsense
  • Outcome Assessment (Health Care)
  • Oxadiazoles
  • Preschool
  • Prospective Studies
  • Time Factors
  • Walking
  • genetic
  • nonsense mutation
  • orphan
  • pediatric

Fingerprint

Dive into the research topics of 'Ataluren treatment of patients with nonsense mutation dystrophinopathy'. Together they form a unique fingerprint.

Cite this